PRESS RELEASE published on 03/09/2026 at 07:30, 6 months 12 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 7 months 3 days ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 7 months 3 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 7 months 3 days ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 7 months 11 days ago GenSight Biologics Begins REVISE Study for GS010 Therapy GenSight Biologics LHON REVISE Study GS010 Therapy 15-20 National Hospital
BRIEF published on 02/10/2026 at 07:35, 7 months 11 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
PRESS RELEASE published on 02/10/2026 at 07:30, 7 months 11 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 7 months 23 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 7 months 23 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 8 months 23 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
Published on 09/21/2026 at 15:45, 4 hours 17 minutes ago Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine
Published on 09/21/2026 at 14:20, 5 hours 42 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 5 hours 57 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 6 hours 2 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 6 hours 17 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 18:00, 2 hours 2 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 09/21/2026 at 17:45, 2 hours 17 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 11-18 September 2026
Published on 09/21/2026 at 17:45, 2 hours 17 minutes ago Charwood Energy continues to grow at a strong pace. H1 revenue up +43% to €5.6m.
Published on 09/21/2026 at 17:00, 3 hours 1 minute ago Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Published on 09/21/2026 at 18:19, 1 hour 43 minutes ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 2 hours ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 2 hours 16 minutes ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 07:00, 13 hours 2 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
